Clinical development of experimental therapies for malignant glioma

Sultan Qaboos University Medical Journal

Volumn 11, Issue 1, 2011, Pages 5-28

  Rainov, Nikolai G ^a   Heidecke, Volkmar ^a  

^a KLINIKUM AUGSBURG   (Germany)

Author keywords

Astrocytoma; Convection enhanced delivery; Glioma; Immunotoxin; Virus

Indexed keywords

EID: 79957960093     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000.
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64:479-89.
3. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg 1998; 88:1-10.
4. Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central brain tumor registry of the United States; surveillance, epidemiology, and end results; and National cancer data base. Neurooncol 1999; 1:205-11.
5. Swanson KR, Alvord EC Jr, Murray JD. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br J Cancer 2002; 86:14-8.
6. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1:459-68.
7. Janus TJ, Kyritsis AP, Forman AD, Levin VA. Biology and treatment of gliomas. Ann Oncol 1992; 3:423-33.
8. Salcman M. Malignant glioma management. Neurosurg Clin N Am 1990; 1:49-63.
9. Schiffer D, Cavalla P, Dutto A, Borsotti L. Cell proliferation and invasion in malignant gliomas. Anticancer Res 1997; 17:61-9.
10. Guha A, Mukherjee J. Advances in the biology of astrocytomas. Curr Opin Neurol 2004; 17:655-62.
11. Mitchell P, Ellison DW, Mendelow AD. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 2005; 4:413-22.
12. Whittle IR. Surgery for gliomas. Curr Opin Neurol 2002; 5:663-9.
13. Giese A, Westphal M. Treatment of malignant glioma: a problem beyond the margins of resection. J Cancer Res Clin Oncol 2001; 127:217-25.
14. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 1994; 30:146-9.
15. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21:1624-36.
16. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114-23.
17. Schiff D, Shaffrey ME. Role of resection for newly diagnosed malignant gliomas. Expert Rev Anticancer Ther 2003; 3:621-30.
18. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96.
19. Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neurooncol 2004; 69:101-17.
20. Rainov NG, Kramm CM. Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curr Gene Ther 2001; 1:367-83.
21. Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 2001; 74:63-7.
22. Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw 2005; 3:721-8.
23. Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991; 74:441-6.
24. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer Brain Tumor Treatment Group. Lancet 1995; 345:1008-12.
25. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 2003; 5:79-88.
26. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir 2006; 148:269-75.
27. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002; 41:403-19.
28. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995; 26:111-23.
29. Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 2004; 22:1-9.
30. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997; 41:44-8.
31. Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2003; 21:1845-9.
32. McGirt MJ, Brem H. Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 2010; 17:1729-31.
33. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009; 110:583-8.
34. Rhines LD, Sampath P, DiMeco F, Lawson HC, Tyler BM, Hanes J, et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery 2003; 52:872-80.
35. Pastan I, Chaudhary VK, Fitzgerald DJ. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 1992; 61:331-54.
36. Pastan I, Fitzgerald D. Recombinant toxins for cancer treatment. Science 1992; 254:1173-7.
37. Hall WA, Fodstad O. Immunotoxins and central nervous system neoplasia. J Neurosurg 1992; 76:1-12.
38. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001; 81:93-124.
39. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003; 65:37-48.
40. Rustamzadeh E, Low WC, Vallera DA, Hall WA. Immunotoxin therapy for CNS tumor. J Neurooncol 2003; 64:101-16.
41. Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A. Immunotoxins: is there a clinical value? Ann Oncol 5 Suppl 1994; 1:97-103.
42. Puri RK, Siegel JP. Interleukin-4 and cancer therapy. Cancer Invest 1993; 11:473-86.
43. The PRECISE Trial: Study of IL13-PE38QQR compared to GLIADEL wafer in patients with recurrent glioblastoma multiforme. From: http://clinicaltrials.gov,studyidentifierNCT00076986. Accessed: July 2010.
44. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994; 58:574-81.
45. Kreitman RJ, Puri PK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA 1994; 91:6889-93.
46. Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted IL-4-toxin in mice with IL-4 receptor bearing human carcinoma. Cancer Res 1995; 55:3357-63.
47. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000; 6:326-34.
48. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 1996; 56:5631-7.
49. Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK. In situ expression of interleukin-4 receptors in human brain tumors and cytotoxicity of a recombinant interleukin-4 (IL-4) cytotoxin in primary glioblastoma cell cultures. Cancer Res 2001; 61:8058-61.
50. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res 1998; 58:3649-53.
51. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003; 64:125-37.
52. NBI-3001 followed by surgery in treating patients with recurrent glioblastoma multiforme. From: http://clinicaltrials.gov,studyidentifierNCT00014677. Accessed: July 2010.
53. Hunter T. The epidermal growth factor receptor gene and its product. Nature 1984; 311:414-6.
54. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987; 84:6899-903.
55. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenographs. Cancer Res 1988; 48:2231-8.
56. Liberman TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression, and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985; 313:144-7.
57. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65:27-35.
58. Weber F. Preliminary results of a phase II study of TP-38 immunotoxin delivered via convection-enhanced delivery to patients with recurrent glioblastoma multiforme: report of the TP-38 study group. Ann Meeting German Soc Neurosurg. From: http://www.egms.de/en/meetings/dgnc2005/05dgnc0094.htm. Accessed: July 2010.
59. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000; 60:1168-72.
60. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002; 8:1948-56.
61. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1995; 1:1253-8.
62. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996; 87:4333-9.
63. Weingart J, Strauss LC, Grossman SA. Phase I/ II study: intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neurooncol 2002; 4:379.
64. Kunwar S. Convection enhanced delivery of IL13- PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003; 88:105-11.
65. Kunwar S, Prados M, Chang S, Berger MS, Lang FF, Piepmeier JM, et al. Peritumoral convectionenhanced delivery of IL13-PE38QQR in patients with recurrent malignant glioma - phase I interim results. Neurooncol 2003; 5:4.
66. Chang SM. Neuroradiographic changes following convection-enhanced delivery (CED) of the conjugated toxin IL13-PE38QQR following resection of recurrent malignant glioma. Neurooncol 2003; 5:4.
67. Prados MD, Lang FF, Stauss LC, Fleming CK, Aldape K, Kunwar S, et al. Intratumoral and intracerebral microinfusion of IL13-PE38QQR cytotoxin: phase I/II study of pre-and post-resection infusions in recurrent resectable maliganant glioma. Proc Am Soc Clin Oncol 2002; 21:2087.
68. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, et al. Phase III randomized trial of CED of IL13-PE38QQR vs. Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010; 12:871-81.
69. Weaver M, Laske DW. Transferrin receptor ligandtargeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003; 65:3-13.
70. Johnson VG, Wilson D, Greenfield L, Youle RJ. The role of the diphtheria toxin receptor in cytosol translocation. J Biol Chem 1988; 263:1295-300.
71. Greenfield L, Johnson VG, Youle RJ. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987; 238:536-9.
72. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain tumor immunotherapy. J Neurosurg 1990; 72:941-5.
73. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 1984; 312:162-3.
74. Johnson VG, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield EH. et al. Improved tumorspecific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 1989; 70:240-8.
75. Hall WA, Godal A, Juell S, Fodstad O. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg 1992; 76:838-44.
76. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 1994; 80:520-6.
77. Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 2002; 97:846-52.
78. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TFCRM107 in patients with malignant brain tumors. Nat Med 1997; 3:1362-8.
79. Study of therapy with TransMID™ compared to best standard of care in patients with glioblastoma multiforme. From: http://clinicaltrials.gov,studyidentifierNCT00083447, see alsoNCT00088400 and NCT00087230. Accessed: July 2010.
80. Celtic Pharma Terminates Transmid Trial KSB311R/ CIII/001.From:http://www.drugs.com/news/celtic-pharma-terminates-transmid-trial-ksb311rciii-001-5246.html. Accessed: July 2010.
81. Briellmann RS, Pell GS, Wellard RM, Mitchell LA, Abbott DF, Jackson GD. MR imaging of epilepsy: state of the art at 1.5 T and potential of 3 T. Epileptic Disord 2003; 5:3-20.
82. Tummala RP, Chu RM, Liu H, Truwit CL, Hall WA. Application of diffusion tensor imaging to magneticresonance- guided brain tumor resection. Ped Neurosurg 2003; 39:39-43.
83. Cruz Junior LC, Sorensen AG. Diffusion tensor magnetic resonance imaging of brain tumors. Neurosurg Clin N Am 2005; 16:115-34.
84. Zlokovic BV, Apuzzo ML. Cellular and molecular neurosurgery: pathways from concept to reality - part II: vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery 1997; 40:805-13.
85. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005; 12:585-98.
86. Coffey MC, Strong JE, Forsyth PA, Lee PW. Retrovirus therapy of tumors with activated Ras pathway. Science 1998; 282:1332-4.
87. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, et al. The potential for efficacy of the modified (ICP 34.5-) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9:398-406.
88. Rainov NG, Kramm CM, Aboody-Guterman K, Chase M, Ueki K, Louis DN, et al. Retrovirusmediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther 1996; 3:99-106.
89. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867-74.
90. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF, et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4:39-69.
91. Rainov NG, Ren H. Gene therapy for human malignant brain tumors. Cancer J 2003; 9:180-8.
92. Muldoon LL, Kroll RA, Pagel MA, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Delivery of therapeutic genes to brain and intracerebral tumors. In: Chiocca EA, Breakefield XO, Eds. Gene therapy for neurological disorders and brain tumors. Boston: Humana Press, 1997. Pp. 128-39.
93. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vectorproducing cells. Nat Med 1997; 3:1354-61.
94. Harsh GR, Deisboeck TS, Louis DN, Hilton J, Colvin M, Silver JS, et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a genemarking and neuropathological study. Neurosurgery 2000; 92:804-11.
95. Ram Z, Barnett G, Vogelbaum M, Constantini S, Lillehei K, Sherman J, et al. Pre-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: A phase I/II study. Proc Am Soc Clin Oncol 2003; 22:403.
96. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57:1502-9.
97. Chiocca EA. Oncolytic viruses. Nat Cancer Rev 2002; 2:938-51.
98. Dirven C, Van Beusechem V, Lamfers M, Grill J, Gerritsen WR, Vandertop WP. Oncolytic adenoviruses for treatment of brain tumours. Expert Opin Biol Ther 2002; 2:943-52.
99. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105:847-51.
100. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc Res 1989; 37:77-102.
101. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11:2389-401.
102. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274-83.
103. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46:5276-81.
104. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum Gene Ther 1998; 9:2595-604.
105. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum Gene Ther 1999; 10:2325-35.
106. Izquierdo M, Cortes ML, Martin V, de Felipe P, Izquierdo JM, Pérez-Higueras A, et al. Gene therapy in brain tumours: implications of the size of glioblastoma on its curability. Acta Neurochir Suppl 1909; 68:111-7.
107. Izquierdo M, Martin V, de Felipe P, Izquierdo JM, Pérez-Higueras A, Cortés ML, et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 1996; 3:491-5.
108. Prados MD, McDermott M, Chang SM, Wilson CB, Fick J, Culver KW, et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vectorproducer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neurooncol 2003; 65:269-78.
109. Puumalainen A, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, et al. ß-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9:1769-74.
110. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC. et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1:195-203.
111. Judy KD, Eck SL. The use of suicide gene therapy for the treatment of malignancies of the brain. In: Lattime EC, Stanton LC, Eds. Gene therapy of cancer. San Diego, CA: Academic Press, 2002. Pp. 505-12.
112. Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65:279-89.
113. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003; 7:851-8.
114. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11:2197-205.
115. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10:967-72.
116. Preliminary Cerepro® Phase III results meet primary endpoint - Secondary endpoints yet to be established with 45% of patients still alive. From: http://www.dggt.de/docs/CereproPhase.pdf. Accessed: July 2010.
117. Mitchell P. Ark's gene therapy stumbles at the finish line. Nat Biotech 2010; 28:183-4.
118. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1:938-43.
119. Markert JM, Parker JN, Gillespie GY, Whitley RJ. Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes 2001; 8:17-22.
120. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7:859-66.
121. Harland J, Papanastassiou V, Brown SM. HSV1716 persistence in primary human glioma cells in vitro. Gene Ther 2002; 9:1194-8.
122. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004; 11:1648-58.
123. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6:879-85.
124. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10:958-66.
125. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-98.
126. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 2009; 9:422-7.
127. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164:2-14.
128. Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 1995; 92:9829-33.